C - Chemistry – Metallurgy – 12 – Q
Patent
C - Chemistry, Metallurgy
12
Q
C12Q 1/68 (2006.01)
Patent
CA 2706672
The invention relates to a method, according to one of Claims 1-6, in which the expression of the gene is determined by measuring the transcription ratio of said gene. The invention also relates to a method, according to one of Claims 1-6, in which the expression of the gene is determined by measuring the translation ratio of said gene. The invention also relates to the use of a modulator of the Early Growth Response 1 transcription factor that can be obtained according to one of Claims 1-8 in order to prepare a drug for the preventive and/or therapeutic treatment of alopecia. The invention also relates to a use according to Claim 9, characterised in that the modulator is an activator of the Early Growth Response 1 transcription factor. The invention also relates to the cosmetic use of a modulator of the Early Growth Response 1 transcription factor for the aesthetic treatment of the scalp. The invention also relates to an in vitro method for diagnosing or following the development of alopecia in a subject, that comprises comparing the expression or the activity of the Early Growth Response 1 protein, or the expression of the gene thereof or the activity of at least one of the promoters thereof in a biological sample from a subject, with a biological sample of a controlled subject. The invention further relates to a method according to Claim 12, in which the expression of the protein is determined by an assay of said protein using an immunoassay. The invention also relates to a method according to Claim 13, in which the immunoassay is an ELISA assay. The invention also relates to a method according to Claim 14, in which the expression of the gene is determined by measuring the amount of the corresponding mRNA.
L'invention concerne une méthode in vitro de criblage de composés candidats pour le traitement préventif ou curatif de l'alopécie, comprenant la détermination de la capacité d'un composé à moduler l'expression ou l'activité du facteur de transcription Early Growth Response 1(EGR1), ainsi que l'utilisation de modulateurs de l'expression ou de l'activité de ce facteur de transcription pour le traitement de l'alopécie. L'invention concerne aussi des méthodes de diagnostic ou pronostic in vitro de cette pathologie.
Galderma Research & Development
Robic
LandOfFree
Egr1 modulators used in the treatment of alopecia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Egr1 modulators used in the treatment of alopecia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Egr1 modulators used in the treatment of alopecia will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1421856